Enovis (ENOV) Reaffirms Guidance On Strong Q2 Sales So Is The Selloff A Bargain
Enovis (ENOV) recently reported second quarter 2026 sales growth, highlighting strong momentum in its Recon segment and the commercial launch of Arvis in the U.S., while management reaffirmed full year guidance.
Despite the solid second quarter update, Enovis shares have lost momentum. The share price is down 30.2% over the past 90 days and the year-to-date share price return is down 33.6%, contributing to a 44.6% decline in 1-year total shareholder return.
Scan beyond Enovis and see how other medical technology players with similar sales momentum and share price pressure stack up by reviewing our curated list of 29 high quality undervalued stocks.
Enovis just reaffirmed guidance while the share price has fallen hard. Does it make more sense to lean into this reset now, or wait and see if sentiment weakens further before putting money to work? How does the current valuation stack up?
Most Popular Narrative: 54% Undervalued
On the most followed view, Enovis carries a fair value estimate of about $38.33 against a last close of $17.61, which frames the recent selloff as a sharp disconnect between price and that long term narrative.
Operational excellence initiatives, including adoption of a disciplined business system (EGX), targeted resource allocation, and optimization of manufacturing and supply chain, are driving ongoing gross margin expansion and improved free cash flow conversion, supporting improved earnings and deleveraging despite near-term headwinds (e.g., tariffs). Enovis's strategy of commercial execution, innovation, and new product launches (e.g., Nebula hip and ARG shoulder systems) aligns with the industry shift toward personalized, patient-centric solutions and value-based care, underpinning expectations for durable organic growth and sustainable expansion of net margins.
See why 4 investors see Enovis as 54% undervalued.
Result: Fair Value of $38.33 (UNDERVALUED)
Still, the Enovis narrative could be knocked off course if integration costs from recent deals drag on margins longer than expected, or if new technology launches face further delays that strain cash generation.
Find out about the key risks to this Enovis narrative.
Next Steps
If the mixed sentiment around Enovis leaves you on the fence, move quickly from headline reactions to hard evidence and build your own thesis using 3 key rewards and 1 important warning sign.
Looking for more Enovis-sized opportunities?
If Enovis has you rethinking what the market is pricing in, do not stop there. Use the Simply Wall Street Screener to uncover fresh ideas before others move.
- Target resilient cash generators by scanning companies with stronger balance sheets and fundamentals using our list of solid balance sheet and fundamentals (25 results).
- Spot potential mispricings early by reviewing a focused set of candidates flagged as 29 high quality undervalued stocks.
- Lock in income ideas by narrowing in on companies screened as 8 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com